97 related articles for article (PubMed ID: 31392461)
1. Outcome of very elderly chronic myeloid leukaemia patients treated with imatinib frontline.
Crugnola M; Castagnetti F; Breccia M; Ferrero D; Trawinska MM; Abruzzese E; Annunziata M; Stagno F; Tiribelli M; Binotto G; Bonifacio M; Fava C; Iurlo A; Bucelli C; Mansueto G; Gozzini A; Falzetti F; Montefusco E; Crisà E; Gugliotta G; Russo S; Cedrone M; RussoRossi A; Pregno P; Isidori A; Mauro E; Atelda R; Giglio G; Celesti F; Sorà F; Storti S; D'Addosio A; Galimberti S; Orlandi E; Calistri E; Bocchia M; Cavazzini F; Rege Cambrin G; Orofino N; Luciano L; Sgherza N; Rosti G; Latagliata R; Capodanno I
Ann Hematol; 2019 Oct; 98(10):2329-2338. PubMed ID: 31392461
[TBL] [Abstract][Full Text] [Related]
2. Chronic myeloid leukemia patients in Tunisia: epidemiology and outcome in the imatinib era (a multicentric experience).
Ben Lakhal R; Ghedira H; Bellaaj H; Ben Youssef Y; Menif S; Manai Z; Bedoui M; Lakhal A; M'Sadek F; Elloumi M; Khélif A; Ben Romdhane N; Laatiri MA; Ben Othmen T; Meddeb B
Ann Hematol; 2018 Apr; 97(4):597-604. PubMed ID: 29305630
[TBL] [Abstract][Full Text] [Related]
3. Five-year follow-up of patients treated with imatinib mesylate for chronic myeloid leukaemia in Trinidad and Tobago.
Charles KS; Ramon L; Leelah N; Oluwabusi TA; Seemungal T
West Indian Med J; 2011 Jun; 60(3):298-302. PubMed ID: 22224342
[TBL] [Abstract][Full Text] [Related]
4. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial.
Lipton JH; Chuah C; Guerci-Bresler A; Rosti G; Simpson D; Assouline S; Etienne G; Nicolini FE; le Coutre P; Clark RE; Stenke L; Andorsky D; Oehler V; Lustgarten S; Rivera VM; Clackson T; Haluska FG; Baccarani M; Cortes JE; Guilhot F; Hochhaus A; Hughes T; Kantarjian HM; Shah NP; Talpaz M; Deininger MW;
Lancet Oncol; 2016 May; 17(5):612-21. PubMed ID: 27083332
[TBL] [Abstract][Full Text] [Related]
5. U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval.
Cohen MH; Johnson JR; Pazdur R
Clin Cancer Res; 2005 Jan; 11(1):12-9. PubMed ID: 15671523
[TBL] [Abstract][Full Text] [Related]
6. Long-term results of high-dose imatinib in children and adolescents with chronic myeloid leukaemia in chronic phase: the Italian experience.
Giona F; Putti MC; Micalizzi C; Menna G; Moleti ML; Santoro N; Iaria G; Ladogana S; Burnelli R; Consarino C; Varotto S; Tucci F; Messina C; Nanni M; Diverio D; Biondi A; Pession A; Locatelli F; Piciocchi A; Gottardi E; Saglio G; Foà R
Br J Haematol; 2015 Aug; 170(3):398-407. PubMed ID: 25891192
[TBL] [Abstract][Full Text] [Related]
7. Long-Term Outcomes after Imatinib Mesylate Discontinuation in Chronic Myeloid Leukemia Patients with Undetectable Minimal Residual Disease.
Yhim HY; Lee NR; Song EK; Yim CY; Jeon SY; Lee B; Kim JA; Kim HS; Cho EH; Kwak JY
Acta Haematol; 2016; 135(3):133-9. PubMed ID: 26535871
[TBL] [Abstract][Full Text] [Related]
8. Imatinib Intolerance Is Associated With Blastic Phase Development in Philadelphia Chromosome-Positive Chronic Myeloid Leukemia.
Ángeles-Velázquez JL; Hurtado-Monroy R; Vargas-Viveros P; Carrillo-Muñoz S; Candelaria-Hernández M
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S82-5. PubMed ID: 27521331
[TBL] [Abstract][Full Text] [Related]
9. Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib.
Castagnetti F; Gugliotta G; Breccia M; Stagno F; Iurlo A; Albano F; Abruzzese E; Martino B; Levato L; Intermesoli T; Pregno P; Rossi G; Gherlinzoni F; Leoni P; Cavazzini F; Venturi C; Soverini S; Testoni N; Alimena G; Cavo M; Martinelli G; Pane F; Saglio G; Rosti G; Baccarani M;
Leukemia; 2015 Sep; 29(9):1823-31. PubMed ID: 26088952
[TBL] [Abstract][Full Text] [Related]
10. Analyses of Treatment Outcome According to Age in Patients With Chronic Myeloid Leukemia Receiving Front-line Imatinib Therapy.
Ćojbašić I; Mačukanović-Golubović L; Vučić M; Tijanić I
Clin Lymphoma Myeloma Leuk; 2017 Oct; 17(10):696-702. PubMed ID: 28712742
[TBL] [Abstract][Full Text] [Related]
11. The predictive value of early molecular response in chronic myeloid leukaemia patients treated with imatinib in a single real-world medical centre in a developing country.
Bee PC; Sekaran V; Ng RR; Kweh TY; Gan GG
Singapore Med J; 2017 Mar; 58(3):150-154. PubMed ID: 27029807
[TBL] [Abstract][Full Text] [Related]
12. First-line imatinib in elderly patients with chronic myeloid leukaemia from the CAMELIA registry: Age and dose still matter.
Belohlavkova P; Steinerova K; Karas M; Skoumalova I; Rohon P; Indrak K; Voglova J; Vrbacky F; Cmunt E; Necasova T; Kristkova Z; Trneny M; Zak P; Papajik T; Faber E
Leuk Res; 2019 Jun; 81():67-74. PubMed ID: 31051328
[TBL] [Abstract][Full Text] [Related]
13. Imatinib mesylate as first-line therapy in patients with chronic myeloid leukemia in accelerated phase and blast phase: a retrospective analysis.
Thota NK; Gundeti S; Linga VG; Coca P; Tara RP;
Indian J Cancer; 2014; 51(1):5-9. PubMed ID: 24947087
[TBL] [Abstract][Full Text] [Related]
14. Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results.
Kantarjian HM; Talpaz M; O'Brien S; Smith TL; Giles FJ; Faderl S; Thomas DA; Garcia-Manero G; Issa JP; Andreeff M; Kornblau SM; Koller C; Beran M; Keating M; Rios MB; Shan J; Resta D; Capdeville R; Hayes K; Albitar M; Freireich EJ; Cortes JE
Clin Cancer Res; 2002 Jul; 8(7):2177-87. PubMed ID: 12114418
[TBL] [Abstract][Full Text] [Related]
15. Effects of Deeper Molecular Responses on Outcomes in Chronic Myeloid Leukemia Patients in Chronic Phase Treated With Imatinib Mesylate.
Kaygusuz Atagunduz I; Toptas T; Deniz R; Kara O; Eser A; Sezgin A; Ozgumus T; Gecgel F; Firatli Tuglular T
Clin Lymphoma Myeloma Leuk; 2017 Feb; 17(2):120-125. PubMed ID: 28082113
[TBL] [Abstract][Full Text] [Related]
16. Reduced-intensity allogeneic hematopoietic stem cell transplantation combined with imatinib has comparable event-free survival and overall survival to long-term imatinib treatment in young patients with chronic myeloid leukemia.
Zhao Y; Wang J; Luo Y; Shi J; Zheng W; Tan Y; Cai Z; Huang H
Ann Hematol; 2017 Aug; 96(8):1353-1360. PubMed ID: 28624905
[TBL] [Abstract][Full Text] [Related]
17. Incidence of Clinically Significant (≤10 g/dL) Late Anemia in Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Imatinib.
Cesini L; Carmosino I; Breccia M; De Benedittis D; Mohamed S; De Luca ML; Colafigli G; Molica M; Scalzulli E; Massaro F; Mariggiò E; Rizzo L; Loglisci MG; Scamuffa MC; Vozella F; Diverio D; Mancini M; Alimena G; Foà R; Latagliata R
Oncol Res Treat; 2019; 42(12):660-664. PubMed ID: 31593970
[TBL] [Abstract][Full Text] [Related]
18. Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial.
Suttorp M; Schulze P; Glauche I; Göhring G; von Neuhoff N; Metzler M; Sedlacek P; de Bont ESJM; Balduzzi A; Lausen B; Aleinikova O; Sufliarska S; Henze G; Strauss G; Eggert A; Kremens B; Groll AH; Berthold F; Klein C; Groß-Wieltsch U; Sykora KW; Borkhardt A; Kulozik AE; Schrappe M; Nowasz C; Krumbholz M; Tauer JT; Claviez A; Harbott J; Kreipe HH; Schlegelberger B; Thiede C
Leukemia; 2018 Jul; 32(7):1657-1669. PubMed ID: 29925908
[TBL] [Abstract][Full Text] [Related]
19. A Retrospective Study of Clinical Profile and Long Term Outcome to Imatinib Mesylate Alone in Childhood Chronic Myeloid Leukemia in Chronic Phase.
Department of Medical and Pediatric Oncology, The Gujarat Cancer and Research Institute, Ahmedabad, Gujarat. INDIA
Gulf J Oncolog; 2017 Jan; 1(23):15-20. PubMed ID: 28271997
[TBL] [Abstract][Full Text] [Related]
20. The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia.
Wang L; Pearson K; Ferguson JE; Clark RE
Br J Haematol; 2003 Mar; 120(6):990-9. PubMed ID: 12648069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
